Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

o, statements about the Company's product development and commercialization schedule, including, particularly, future plans with respect to its Amoxicillin PULSYS products; any statements regarding Dr. Rudnic's comments and expectations concerning the Company; the Company's initiatives to develop improved antibiotics; the Company's existing and anticipated collaborative agreements; and any financial forecasts and projections for 2008 and thereafter included under the Financial Guidance section of this announcement.

The actual results realized by MiddleBrook could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company's filings with the Securities and Exchange Commission. These include, without limitation, risks and uncertainties relating to the Company's financial results and the ability of the Company to (1) raise additional capital and continue as a going concern, (2) maintain its Keflex 750 sales, (3) retain marketing approval for its MOXATAG product, (4) successfully reduce costs, (5) reach profitability, (6) prove that the preliminary findings for its product candidates are valid, (7) receive required regulatory approvals, (8) successfully conduct clinical trials in a timely manner, (9) establish its competitive position for its products, (10) develop and commercialize products that are superior to existing or newly developed competitor products, (11) develop products without any defects, (12) have sufficient capital resources to fund its operations, (13) protect its intellectual property rights and patents, (14) implement its sales and marketing strategy, (15) successfully attract and retain collaborative partners, (16) successfully commercialize and gain market acceptance for its Keflex products, (17) successfully obtain sufficient manufactured quantities of its drug products at acceptable rates, and (18) retain its senior management and other personnel. Existing and pr
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Albany, NY (PRWEB) February 26, 2015 ... Market Research “Agricultural Biotechnology Market For Transgenic Crops (Corn, ... – Global Industry Analysis, Size, Share, Growth, Trends and ... valued at USD 15,300 million in 2012 and is ... at a CAGR of 9.5% from 2013 to 2019. ...
(Date:2/26/2015)... Regis Technologies announced new potent compound ... substances. , Regis Technologies is proud to announce the ... Suite (PCS) for 2015. , Regis is a contract ... in Morton Grove, Illinois. The PCS addition will provide ... to about one kilogram per batch. , Regis’ ...
(Date:2/26/2015)... , Feb. 26, 2015 Tauriga Sciences, Inc. ... company with interests in the natural wellness sector and ... today that its products will be featured at the ... Partners, 27 th Annual Growth Stock Conference on ... at 1 Ritz Carlton Drive, Dana Point ...
(Date:2/26/2015)... --  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) ... 35 th Annual Health Care Conference on Tuesday, March ... .  Lexicon management will provide an overview of Lexicon,s ... the presentation will be available through Lexicon,s website at ... available at www.lexpharma.com until April 3, 2015. ...
Breaking Biology Technology:Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Lexicon To Present At The Cowen 35th Annual Health Care Conference 2
... governor and then secretary of the U.S. Department of ... with Alfacell Corporation. , ,Alfacell develops cancer theraputics and ... with the federal Food and Drug Administration for its ... New Jersy, but it has a local presence. , ...
... patched the Windows vulnerability that could allow malicious programs to ... security experts say the same part of Windows has even ... ,Giving in to pressure from users and security experts, some ... the company, Microsoft released the official patch days earlier than ...
... — QBI Life Sciences said it has ... formed partnerships with UW-Madison and the University of Helsinki, ... division of Quintessence Biosciences Inc. in Madison, will be ... harmful interactions between different drugs given to the same ...
Cached Biology Technology:
(Date:2/12/2015)... , Feb. 12, 2015   MedNet ... specializing in clinical study management systems, has recently ... , further distinguishing iMedNet ... Research Organizations (CROs) and healthcare consultants.  Building on ... prospective customer referrals and numerous co-marketing opportunities), MedNet,s ...
(Date:2/5/2015)... , 5. Februar 2015 ... spezialisiertes Logistikunternehmen und hat eine neue Marketingkampagne ... Logistikfirma (Clinical Logistics Organization – CLO) der ... Kampagne lautet First , mit Schwerpunkt ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 Logo ...
(Date:2/5/2015)... SAN FRANCISCO , January 28, 2015 ... Camera Market Analysis, Size And Segment Forecasts To 2020 ... The global IR camera market is expected to reach ... study by Grand View Research, Inc. IR cameras help ... injuries, and are expected to witness surging demand in ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... name, indicates a disease of the respiratory tract. But ... nervous system problems, according to an article in the ... online. , SARS, a potentially fatal illness caused by ... of 2003. The disease is usually transmitted by contact ...
... the most common childhood cancer is cured in about ... number was closer to five percent. In efforts to ... Children's Research Hospital, the University of Tennessee, and the ... play a role in the effectiveness of chemotherapy drugs. ...
... on earth, there were organic molecules that combined to ... first elements able to self-replicate. According to one of ... (RNA) chains, a molecule that is practically identical to ... cells of copying information stored in DNA and translating ...
Cached Biology News:New study shows SARS can infect brain tissue 2Genes linked to treatment resistance in children with leukemia 2Life's origins were easier than was thought 2
Request Info...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Biology Products: